NDLI: Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma

Please wait, while we are loading the content...

The use of bone cement for the localized, controlled release of the antibiotics vancomycin, linezolid, or fusidic acid: effect of additives on drug release rates and mechanical strength

Design and evaluation of matrix base with sigmoidal release profile for colon-specific delivery using a combination of Eudragit and non-ionic cellulose ether polymers

Nanofibrous scaffold with incorporated protein gradient for directing neurite outgrowth

Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma

Preclinical evaluation of UC781 microbicide vaginal drug delivery

Drug Delivery and Translational Research : Volume 1, Issue 1, February 2011

Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma

Content Provider	Springer Nature Link
Author	Bhagav, Prakash Trivedi, Vaibhav Shah, Darshan Chandran, Sajeev
Copyright Year	2011
Abstract	Pathology of eye, especially in the case of glaucoma, requires optimal therapeutically effective concentration of the drug in the ocular tissues for prolonged period of time with decreased dosing frequency and improved patient compliance. In the present study, brimonidine tartrate (BRT) ocular inserts were designed based on hydrophilic and/or inert/zwitterionic polymer matrix to design mucoadhesive and extended release ocular inserts. Designed inserts were evaluated for their physicochemical properties such as crushing strength/hardness, friability, drug content and mucoadhesion, and erosion and in vitro drug release characteristics. The selected optimised formulations were compared with marketed preparation for in vivo ocular irritation in healthy rabbits and for in vivo pharmacodynamic efficacy on alpha-chymotrypsin-induced glaucomatous rabbits. The developed formulations showed good physicochemical properties and mucoadhesive strength, and a good correlation was seen between rate of erosion or swelling with drug release rate in case of formulations with higher proportion of polyethylene oxide (PEO). Modulation of drug release was achieved by incorporating Eudragit in PEO matrix. Addition of Eudragit resulted in shifting of drug release mechanism from erosion-controlled to diffusion-controlled mechanism. In vivo ocular irritation studies confirmed the absence of any irritation upon administration in rabbits. Intraocular pressure (IOP) measurement studies showed an improved IOP-lowering ability of ocular insert of BRT in comparison to eye drops.
Starting Page	161
Ending Page	174
Page Count	14
File Format	PDF
ISSN	2190393X
Journal	Drug Delivery and Translational Research
Volume Number	1
Issue Number	2
e-ISSN	21903948
Language	English
Publisher	Springer US
Publisher Date	2011-02-15
Publisher Institution	Controlled Release Society
Publisher Place	Boston
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Brimonidine tartrate Glaucoma Ocular inserts Intraocular pressure Polyethylene oxide Eudragit Pharmaceutical Sciences/Technology
Content Type	Text
Resource Type	Article
Subject	Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Biodegradable Ocular Inserts for Sustained Delivery of Brimonidine Tartarate: Preparation and In Vitro/In Vivo Evaluation

Chick chorioallantoic membrane model for in ovo evaluation of timolol maleate–brimonidine tartrate ocular inserts

The Effect of Latanoprost, Brimonidine, and a Fixed Combination of Timolol and Dorzolamide on Circadian Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension

A biodegradable ocular implant for long-term suppression of intraocular pressure

Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma.

Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension

Efficacy, safety, and current applications of brimonidine.

Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration.

Brimonidine for glaucoma.

Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma

Similar Documents

Biodegradable Ocular Inserts for Sustained Delivery of Brimonidine Tartarate: Preparation and In Vitro/In Vivo Evaluation

Chick chorioallantoic membrane model for in ovo evaluation of timolol maleate–brimonidine tartrate ocular inserts

The Effect of Latanoprost, Brimonidine, and a Fixed Combination of Timolol and Dorzolamide on Circadian Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension

A biodegradable ocular implant for long-term suppression of intraocular pressure

Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma.

Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension

Efficacy, safety, and current applications of brimonidine.

Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration.

Brimonidine for glaucoma.

Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma